[go: up one dir, main page]

EA200600735A1 - Нуклеиновые кислоты, специфично связывающие биоактивный грелин - Google Patents

Нуклеиновые кислоты, специфично связывающие биоактивный грелин

Info

Publication number
EA200600735A1
EA200600735A1 EA200600735A EA200600735A EA200600735A1 EA 200600735 A1 EA200600735 A1 EA 200600735A1 EA 200600735 A EA200600735 A EA 200600735A EA 200600735 A EA200600735 A EA 200600735A EA 200600735 A1 EA200600735 A1 EA 200600735A1
Authority
EA
Eurasian Patent Office
Prior art keywords
greeline
nucleic acids
specifically binding
binding bioactive
bioactive
Prior art date
Application number
EA200600735A
Other languages
English (en)
Other versions
EA009376B1 (ru
Inventor
Свен КЛУССМАНН
Штеффен Хельмлинг
Дирк Эульберг
Кристиан Маш
Клаус БУХНЕР
Original Assignee
Нокссон Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нокссон Фарма Аг filed Critical Нокссон Фарма Аг
Publication of EA200600735A1 publication Critical patent/EA200600735A1/ru
Publication of EA009376B1 publication Critical patent/EA009376B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)

Abstract

Настоящее изобретение относится к нуклеиновой кислоте, специфично связывающей биоактивный грелин, более предпочтительно н-октаноил-грелин, и к ее применению для диагностики заболеваний и расстройств, опосредованных грелином.
EA200600735A 2003-11-10 2004-11-10 Нуклеиновые кислоты, специфично связывающие биоактивный грелин EA009376B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03025743 2003-11-10
PCT/EP2004/012739 WO2005049828A1 (en) 2003-11-10 2004-11-10 Nucleic acids specifically binding bioactive ghrelin

Publications (2)

Publication Number Publication Date
EA200600735A1 true EA200600735A1 (ru) 2006-10-27
EA009376B1 EA009376B1 (ru) 2007-12-28

Family

ID=34610046

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600735A EA009376B1 (ru) 2003-11-10 2004-11-10 Нуклеиновые кислоты, специфично связывающие биоактивный грелин

Country Status (19)

Country Link
US (2) US20070031840A1 (ru)
EP (1) EP1682662A1 (ru)
JP (1) JP4823067B2 (ru)
KR (1) KR20060125743A (ru)
CN (1) CN1894407A (ru)
AP (1) AP2006003618A0 (ru)
AU (1) AU2004291656A1 (ru)
BR (1) BRPI0415872A (ru)
CA (1) CA2544805A1 (ru)
CR (1) CR8388A (ru)
EA (1) EA009376B1 (ru)
EC (1) ECSP066559A (ru)
IL (1) IL175443A0 (ru)
MA (1) MA28153A1 (ru)
NO (1) NO20062663L (ru)
OA (1) OA13282A (ru)
TN (1) TNSN06132A1 (ru)
WO (1) WO2005049828A1 (ru)
ZA (1) ZA200603435B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013274A2 (en) * 2002-08-01 2004-02-12 Noxxon Pharma Ag Ghrelin binding nucleic acids
US7888010B2 (en) * 2004-05-28 2011-02-15 Asuragen, Inc. Methods and compositions involving microRNA
EP2808389A1 (en) 2004-11-12 2014-12-03 Asuragen, Inc. Methods and compositions involving MIRNA and MIRNA inhibitor molecules
AR052741A1 (es) * 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
EP2145001A2 (en) * 2006-09-19 2010-01-20 Asuragen, Inc. Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
JP5520605B2 (ja) * 2006-09-19 2014-06-11 アシュラジェン インコーポレイテッド 膵臓疾患で差次的に発現されるマイクロｒｎａおよびその使用
WO2008073920A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
CA2671299A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Functions and targets of let-7 micro rnas
CN101622350A (zh) * 2006-12-08 2010-01-06 奥斯瑞根公司 作为干预治疗靶标的miR-126调控基因和通路
US20090175827A1 (en) * 2006-12-29 2009-07-09 Byrom Mike W miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090131354A1 (en) * 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
AU2008261951A1 (en) * 2007-06-08 2008-12-18 Asuragen, Inc. miR-34 regulated genes and pathways as targets for therapeutic intervention
EP2198050A1 (en) 2007-09-14 2010-06-23 Asuragen, INC. Micrornas differentially expressed in cervical cancer and uses thereof
WO2009052386A1 (en) * 2007-10-18 2009-04-23 Asuragen, Inc. Micrornas differentially expressed in lung diseases and uses thereof
WO2009070805A2 (en) * 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
US20090192114A1 (en) * 2007-12-21 2009-07-30 Dmitriy Ovcharenko miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention
EP2260110B1 (en) * 2008-02-08 2014-11-12 Asuragen, INC. miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
EP2268832A2 (en) * 2008-03-06 2011-01-05 Asuragen, INC. Microrna markers for recurrence of colorectal cancer
EP2271757A2 (en) * 2008-03-26 2011-01-12 Asuragen, INC. Compositions and methods related to mir-16 and therapy of prostate cancer
EP2990487A1 (en) 2008-05-08 2016-03-02 Asuragen, INC. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
US20100179213A1 (en) * 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells
CA2778990A1 (en) 2009-10-30 2011-05-05 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
CN103339258A (zh) * 2011-01-10 2013-10-02 诺松制药股份公司 具有对于靶分子的结合亲和力的核酸分子及产生所述核酸分子的方法
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614395A (en) * 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
EP1695978A1 (en) * 1990-06-11 2006-08-30 Gilead Sciences, Inc. Nucleic acid ligands
CA2218083A1 (en) * 1995-05-03 1996-11-07 Antonius Nicolaas Maria Schumacher Identification of enantiomeric ligands
US5780221A (en) * 1995-05-03 1998-07-14 Whitehead Institute For Biomedical Research Identification of enantiomeric ligands
AU2001259056A1 (en) * 2000-05-17 2001-11-26 Eli Lilly And Company Method for selectively inhibiting ghrelin action
US20030211967A1 (en) * 2001-05-07 2003-11-13 Bryant Henry Uhlman Method for selectively inhibiting ghrelin action
WO2001092292A2 (en) * 2000-05-30 2001-12-06 Merck & Co., Inc. Ghrelin analogs
WO2004013274A2 (en) * 2002-08-01 2004-02-12 Noxxon Pharma Ag Ghrelin binding nucleic acids
AR052741A1 (es) * 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin

Also Published As

Publication number Publication date
NO20062663L (no) 2006-08-09
US20070031840A1 (en) 2007-02-08
CN1894407A (zh) 2007-01-10
ZA200603435B (en) 2007-06-27
AU2004291656A1 (en) 2005-06-02
KR20060125743A (ko) 2006-12-06
EP1682662A1 (en) 2006-07-26
JP4823067B2 (ja) 2011-11-24
IL175443A0 (en) 2006-09-05
CA2544805A1 (en) 2005-06-02
US20100261291A1 (en) 2010-10-14
AP2006003618A0 (en) 2006-06-30
WO2005049828A1 (en) 2005-06-02
MA28153A1 (fr) 2006-09-01
CR8388A (es) 2006-10-17
OA13282A (en) 2007-01-31
ECSP066559A (ru) 2006-11-24
BRPI0415872A (pt) 2007-01-09
EA009376B1 (ru) 2007-12-28
TNSN06132A1 (fr) 2007-11-15
JP2007513608A (ja) 2007-05-31

Similar Documents

Publication Publication Date Title
EA200600735A1 (ru) Нуклеиновые кислоты, специфично связывающие биоактивный грелин
NL300919I2 (nl) Brodalumab
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
MY139541A (en) Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
CY1109104T1 (el) 1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου
ATE485517T1 (de) Verfahren zur identifizierung von polypeptid- targets
EA200970262A1 (ru) Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
SE0301010D0 (sv) Novel compounds
SE0301009D0 (sv) Novel compounds
TW200612892A (en) Novel compounds
PT1206474E (pt) Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2
DK1768677T3 (da) Nucleinsyrer til behandling af HMGB1-relaterede patologier
EA200500007A1 (ru) Пролекарства возбуждающих аминокислот
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
ATE514714T1 (de) Hutnfr1-selektive antagonisten
WO2004058174A3 (en) Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
EA200601219A1 (ru) Новые конденсированные пирролокарбазолы
BRPI0516027A (pt) compostos de sulfonamida
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo
WO2006058869A8 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
MX2007006357A (es) Pteridinas sustituidas para el tratamiento de enfermedades inflamatorias.
ATE496913T1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
ATE513041T1 (de) Ghrelin bindende nukleinsäuren
WO2006135694A3 (en) Uii-modulating compounds and their use

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU